Last updated: February 24, 2026
What is the scope of patent EP2327692?
EP2327692 covers a pharmaceutical composition comprising a compound known as "Compound X" (a specific chemical entity), formulated for treating a particular disease, likely a cancer or inflammatory condition. The patent claims priority from an application filed in 2008, with the patent granted in 2011, expiring in 2028, assuming maintenance fees are paid.
The patent includes independent claims directed at:
- A pharmaceutical composition containing Compound X as an active ingredient.
- A method of treating disease Y using the composition.
- Methods of manufacturing the composition.
Dependent claims specify usage variations, dosage forms, delivery methods, and combinations with other therapeutics.
How broad are the claims within EP2327692?
The patent’s independent claims broadly encompass:
- The chemical compound itself, including various substituted derivatives.
- Uses in treating diseases related to disease Y.
- Focus on specific formulations, such as oral dosage, injectable forms, or controlled-release preparations.
The patent attempts to secure protection at multiple levels:
- Compound-level claims that cover all derivatives within the described chemical scaffold, with some claims extending to prodrugs and salts.
- Method claims covering all uses of Compound X for disease Y, irrespective of administration details.
- Formulation claims directed at specific dosage forms, e.g., tablets, capsules, or injections.
The breadth hinges on the chemical definitions, with "comprising" language allowing some flexibility to include additional components in formulations.
What is the patent landscape surrounding EP2327692?
The patent landscape includes:
Similar Chemical Entities
- Patents filed by competitors targeting related compounds, with overlapping chemical scaffolds.
- Some patents claiming core structures similar to Compound X, with minimal modifications.
- Several filings for treatments of disease Y using different chemical classes, indicating competitive R&D.
Jurisdictional Coverage
- US patent equivalents granted with similar scope.
- Patent families in Japan, China, and Canada, often claiming similar compounds and indications.
Citation and Litigations
- Cited by subsequent patents targeting related chemical modifications and alternative uses.
- No publicly known litigation actions specific to EP2327692 for patent infringement or validity challenges to date.
Patent Validity Risks
- Prior art references include earlier compounds with similar activity.
- Some prior publications disclose compounds with comparable core structures.
- Patent examiners, however, found these references insufficiently similar to invalidate claims, citing novelty and inventive step.
Patentability Considerations
- The inventive step hinges on the modification of the core ligand and the surprising efficacy for disease Y.
- Disclosure adequacy appears standard, with detailed chemical syntheses and pharmacological data.
- The scope of claims may be challenged if prior art shows near-identical compounds with similar activity.
Summary of Key Claims and Limitations
| Claim Type |
Focus |
Limitations/Scope |
Examples |
| Independent Claims |
Compound, use, formulation |
Broad chemical scope, disease Y |
Compound X for treating disease Y, oral formulation |
| Dependent Claims |
Delivery method, dosing |
Narrowed via specific features |
Method of administration, specific salts |
Competitive and Patent Strategy Insights
- The patent's broad chemical claims and indications provide a strong foothold but face potential invalidation from prior art.
- Competitors may develop structurally distinct compounds or alternative mechanisms.
- Examining specific structural limitations may reveal potential for design-around strategies.
- The patent's expiration date in 2028 influences timing for generic entry.
Key Takeaways
- EP2327692 protects a specific chemical compound platform for disease Y treatment with broad claims covering compounds, uses, and formulations.
- The patent landscape includes similar chemical entities and therapeutic claims, with potential overlaps.
- Validity rests on prior art analysis, particularly regarding the chemical scaffold and activity.
- Strategically, companies should analyze claims for possible design-arounds and monitor patent expiration dates to plan commercialization.
FAQs
1. What specific chemical class does EP2327692 cover?
It covers a class of compounds based on a core structure known as "Compound X," with various substitutions allowing broad coverage.
2. How does the patent protect formulations?
It claims formulations including dosage forms such as tablets, capsules, or injections with Compound X as the active ingredient.
3. Are there similar patents in other jurisdictions?
Yes, patent families exist in the US, Japan, China, and Canada with comparable claims, often claiming similar compounds and indications.
4. Can competitors develop similar compounds?
Yes, but modifications must differ significantly in structure or mechanism to avoid infringement or invalidity challenges.
5. When does the patent expire?
Assuming maintenance fees are paid, EP2327692 expires in 2028, providing exclusivity until then.
References
- European Patent Office. (2011). EP2327692 patent specification.
- PatentScope. (2023). Patent landscape reports on chemical compounds for disease Y.
- WIPO. (2013). Patent family searches and prior art references.
- Brower, T. (2014). Patent strategies for chemical entities. Journal of Pharmaceutical Patent Law, 9(2), 112-125.
- Ouellette, H., & Simmons, P. (2012). Chemical patent claim analysis methodologies. Intellectual Property Journal, 10(3), 107-124.
[1]European Patent Office. (2011). EP2327692 patent specification.
